[
    {
        "id": 5865,
        "drug_name": "RITUXAN (rituximab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Granulomatosis with polyangiitis (GPA) \/ microscopic polyangiitis (MPA)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-27",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20190927005432\/en\/FDA-Approves-Genentech%E2%80%99s-Rituxan-rituximab-Children-Rare",
        "note": "FDA Approval announced September 27, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2875,
        "drug_name": "INVOKANA (canagliflozin)",
        "clinical_trial_id": "NCT02065791",
        "has_trial_insight_page": 0,
        "indication": "Diabetic Kidney Disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-30",
        "link": "https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/0f9e4a30-89e0-4518-8cd8-b5b6f2d5f89a",
        "note": "FDA Approval announced September 30, 2019.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2317,
        "drug_name": "DESCOVY",
        "clinical_trial_id": "NCT02842086",
        "has_trial_insight_page": 0,
        "indication": "Pre-exposure prophylaxis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-03",
        "link": "http:\/\/investors.gilead.com\/news-releases\/news-release-details\/us-food-and-drug-administration-approves-descovyr-hiv-pre",
        "note": "FDA Approval announced October 3, 2019.",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2284,
        "drug_name": "PF708",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Osteoporosis ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-07",
        "link": "http:\/\/www.globenewswire.com\/news-release\/2019\/10\/07\/1925635\/0\/en\/Pfenex-Receives-U-S-FDA-Approval-for-PF708-to-Treat-Osteoporosis.html",
        "note": "FDA approval announced October 7, 2019.",
        "company_entity_id": 627,
        "company_ticker": "LGND",
        "company_name": "Ligand Pharmaceuticals Incorporated",
        "company_price": "72.3600",
        "company_change": 0.11,
        "company_percent_change": 0.15,
        "company_optionable": 1,
        "company_number_of_shares": 17705287,
        "price_change_sparkline": [
            [
                73.1,
                1706677200
            ],
            [
                74.17,
                1706763600
            ],
            [
                74.54,
                1706850000
            ],
            [
                74.72,
                1707109200
            ],
            [
                75.31,
                1707195600
            ],
            [
                74.51,
                1707282000
            ],
            [
                75.41,
                1707368400
            ],
            [
                75.88,
                1707454800
            ],
            [
                75.64,
                1707714000
            ],
            [
                71,
                1707800400
            ],
            [
                73.62,
                1707886800
            ],
            [
                74.65,
                1707973200
            ],
            [
                73.66,
                1708059600
            ],
            [
                72.37,
                1708405200
            ],
            [
                72.67,
                1708491600
            ],
            [
                73.56,
                1708578000
            ],
            [
                75.87,
                1708664400
            ],
            [
                74.42,
                1708923600
            ],
            [
                89.2,
                1709010000
            ],
            [
                84.35,
                1709096400
            ],
            [
                79.35,
                1709182800
            ],
            [
                78.7,
                1709269200
            ],
            [
                76.28,
                1709528400
            ],
            [
                74,
                1709614800
            ],
            [
                72.71,
                1709701200
            ],
            [
                72.47,
                1709787600
            ],
            [
                73.77,
                1709874000
            ],
            [
                72.25,
                1710129600
            ],
            [
                72.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2821,
        "drug_name": "BEOVU (brolucizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Wet age-related macular degeneration (AMD) ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-08",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/18515108-e406-452b-8b65-0dce32157deb",
        "note": "FDA Approval announced October 8, 2019.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2768,
        "drug_name": "REYVOW (lasmiditan",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-11",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-reyvowtm-lasmiditan-first-and-only-medicine-new-class",
        "note": "FDA Approval announced October 11, 2019.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2492,
        "drug_name": "XARELTO (rivaroxaban)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Reduce the Risk of Recurrent Venous Thromboembolism (VTE)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-14",
        "link": "https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/d6da0de4-5867-404d-bb23-89cad9b86608",
        "note": "FDA approval announced October 14, 2019.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5559,
        "drug_name": "XOFLUZA (baloxavir marboxil)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Influenza",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-18",
        "link": "https:\/\/www.roche.com\/media\/releases\/med-cor-2019-10-18.htm",
        "note": "FDA Approval announced October 18, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3536,
        "drug_name": "AMZEEQ (FMX101)",
        "clinical_trial_id": "NCT03271021",
        "has_trial_insight_page": 0,
        "indication": "Acne",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-18",
        "link": "http:\/\/investors.foamix.com\/news-releases\/news-release-details\/update-foamix-receives-fda-approval-amzeeqtm-topical-minocycline",
        "note": "FDA Approval announced October 18, 2019.",
        "company_entity_id": 875,
        "company_ticker": "VYNE",
        "company_name": "VYNE Therapeutics Inc.",
        "company_price": "2.1000",
        "company_change": -0.040000000000000036,
        "company_percent_change": -1.87,
        "company_optionable": 0,
        "company_number_of_shares": 14098888,
        "price_change_sparkline": [
            [
                1.71,
                1706677200
            ],
            [
                1.82,
                1706763600
            ],
            [
                1.9,
                1706850000
            ],
            [
                2.1,
                1707109200
            ],
            [
                2.11,
                1707195600
            ],
            [
                2.15,
                1707282000
            ],
            [
                2.14,
                1707368400
            ],
            [
                2.14,
                1707454800
            ],
            [
                2.07,
                1707714000
            ],
            [
                2.01,
                1707800400
            ],
            [
                2.07,
                1707886800
            ],
            [
                2.16,
                1707973200
            ],
            [
                2.27,
                1708059600
            ],
            [
                2.23,
                1708405200
            ],
            [
                2.17,
                1708491600
            ],
            [
                2.17,
                1708578000
            ],
            [
                2.26,
                1708664400
            ],
            [
                2.35,
                1708923600
            ],
            [
                2.37,
                1709010000
            ],
            [
                2.33,
                1709096400
            ],
            [
                2.23,
                1709182800
            ],
            [
                2.22,
                1709269200
            ],
            [
                2.28,
                1709528400
            ],
            [
                2.25,
                1709614800
            ],
            [
                2.35,
                1709701200
            ],
            [
                2.32,
                1709787600
            ],
            [
                2.245,
                1709874000
            ],
            [
                2.14,
                1710129600
            ],
            [
                2.1,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3001,
        "drug_name": "ULTOMIRIS (ravulizumab-cwvz)",
        "clinical_trial_id": "NCT02949128",
        "has_trial_insight_page": 0,
        "indication": "atypical Hemolytic Uremic Syndrome (aHUS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-18",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20191018005600\/en\/",
        "note": "FDA Approval announced October 18, 2019.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5357,
        "drug_name": "NPLATE (Romiplostim)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Immune thrombocytopenia (ITP) ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-18",
        "link": "http:\/\/investors.amgen.com\/news-releases\/news-release-details\/nplater-romiplostim-now-approved-earlier-use-adults-immune",
        "note": "FDA Approval announced October 18, 2019.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2504,
        "drug_name": "FARXIGA (Dapagliflozin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Heart failure in patients with type-2 diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-21",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-21102019.html",
        "note": "FDA Approval announced October 21, 2019.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4671,
        "drug_name": "TRIKAFTA (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor)",
        "clinical_trial_id": "NCT03525444",
        "has_trial_insight_page": 0,
        "indication": "Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-21",
        "link": "https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/fda-approves-trikafta-elexacaftortezacaftorivacaftor-and",
        "note": "FDA Approval announced October 21, 2019.",
        "company_entity_id": 306,
        "company_ticker": "VRTX",
        "company_name": "Vertex Pharmaceuticals Incorporated",
        "company_price": "412.4500",
        "company_change": -2.02,
        "company_percent_change": -0.49,
        "company_optionable": 1,
        "company_number_of_shares": 258307816,
        "price_change_sparkline": [
            [
                433.38,
                1706677200
            ],
            [
                433.87,
                1706763600
            ],
            [
                424.68,
                1706850000
            ],
            [
                428.89,
                1707109200
            ],
            [
                416.13,
                1707195600
            ],
            [
                419.08,
                1707282000
            ],
            [
                423.06,
                1707368400
            ],
            [
                422.91,
                1707454800
            ],
            [
                418.53,
                1707714000
            ],
            [
                416.04,
                1707800400
            ],
            [
                417.88,
                1707886800
            ],
            [
                426.29,
                1707973200
            ],
            [
                422.2,
                1708059600
            ],
            [
                420.64,
                1708405200
            ],
            [
                419.63,
                1708491600
            ],
            [
                426.78,
                1708578000
            ],
            [
                430.11,
                1708664400
            ],
            [
                433.48,
                1708923600
            ],
            [
                430.92,
                1709010000
            ],
            [
                426.97,
                1709096400
            ],
            [
                420.74,
                1709182800
            ],
            [
                432.76,
                1709269200
            ],
            [
                424.03,
                1709528400
            ],
            [
                415.44,
                1709614800
            ],
            [
                411.85,
                1709701200
            ],
            [
                410.54,
                1709787600
            ],
            [
                413.59,
                1709874000
            ],
            [
                414.47,
                1710129600
            ],
            [
                412.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5421,
        "drug_name": "STELARA (USTEKINUMAB)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ulcerative colitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-21",
        "link": "https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/588ec425-d581-4828-a9a1-88354dab7d82",
        "note": "FDA Approval announced October 21, 2019.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5609,
        "drug_name": "Biorphen (ET-202)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Injectable hospital product",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-22",
        "link": "https:\/\/ir.etonpharma.com\/news-releases\/news-release-details\/eton-pharmaceuticals-announces-us-fda-approval-biorphenr",
        "note": "FDA Approval announced October 22, 2019.",
        "company_entity_id": 611,
        "company_ticker": "ETON",
        "company_name": "Eton Pharmaceuticals Inc.",
        "company_price": "4.4000",
        "company_change": -0.16000000000000003,
        "company_percent_change": -3.51,
        "company_optionable": 1,
        "company_number_of_shares": 25658396,
        "price_change_sparkline": [
            [
                4.67,
                1706677200
            ],
            [
                4.6,
                1706763600
            ],
            [
                4.49,
                1706850000
            ],
            [
                4.58,
                1707109200
            ],
            [
                4.72,
                1707195600
            ],
            [
                4.58,
                1707282000
            ],
            [
                4.41,
                1707368400
            ],
            [
                4.41,
                1707454800
            ],
            [
                4.41,
                1707714000
            ],
            [
                4.42,
                1707800400
            ],
            [
                4.39,
                1707886800
            ],
            [
                4.59,
                1707973200
            ],
            [
                4.4,
                1708059600
            ],
            [
                4.36,
                1708405200
            ],
            [
                4.45,
                1708491600
            ],
            [
                4.47,
                1708578000
            ],
            [
                4.47,
                1708664400
            ],
            [
                4.47,
                1708923600
            ],
            [
                4.49,
                1709010000
            ],
            [
                4.48,
                1709096400
            ],
            [
                4.45,
                1709182800
            ],
            [
                4.46,
                1709269200
            ],
            [
                4.47,
                1709528400
            ],
            [
                4.38,
                1709614800
            ],
            [
                4.33,
                1709701200
            ],
            [
                4.49,
                1709787600
            ],
            [
                4.5,
                1709874000
            ],
            [
                4.56,
                1710129600
            ],
            [
                4.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3824,
        "drug_name": "ZEJULA (Niraparib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ovarian cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-23",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20191023005902\/en\/",
        "note": "FDA Approval announced October 23, 2019.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5570,
        "drug_name": "BOTOX",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Lower limb spasticity",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-24",
        "link": "https:\/\/www.benzinga.com\/pressreleases\/19\/10\/n14652768\/fda-approves-botox-onabotulinumtoxina-for-pediatric-patients-with-lower-limb-spasticity-excluding-",
        "note": "FDA Approval announced October 24, 2019.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3904,
        "drug_name": "VUMERITY (Diroximel fumarate)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple sclerosis (MS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-30",
        "link": "http:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-alkermes-announce-fda-approval-vumeritytm-diroximel",
        "note": "FDA Approval announced October 30, 2019.",
        "company_entity_id": 31,
        "company_ticker": "ALKS",
        "company_name": "Alkermes plc",
        "company_price": "28.4700",
        "company_change": -0.13,
        "company_percent_change": -0.44999999999999996,
        "company_optionable": 1,
        "company_number_of_shares": 167076133,
        "price_change_sparkline": [
            [
                27.05,
                1706677200
            ],
            [
                26.94,
                1706763600
            ],
            [
                26.74,
                1706850000
            ],
            [
                26.4,
                1707109200
            ],
            [
                27.04,
                1707195600
            ],
            [
                26.7,
                1707282000
            ],
            [
                26.77,
                1707368400
            ],
            [
                27.32,
                1707454800
            ],
            [
                28.52,
                1707714000
            ],
            [
                27.23,
                1707800400
            ],
            [
                27.99,
                1707886800
            ],
            [
                32.56,
                1707973200
            ],
            [
                32.18,
                1708059600
            ],
            [
                30.39,
                1708405200
            ],
            [
                29.18,
                1708491600
            ],
            [
                28.91,
                1708578000
            ],
            [
                29.57,
                1708664400
            ],
            [
                30.04,
                1708923600
            ],
            [
                29.7,
                1709010000
            ],
            [
                29.8,
                1709096400
            ],
            [
                29.69,
                1709182800
            ],
            [
                30.24,
                1709269200
            ],
            [
                29.92,
                1709528400
            ],
            [
                29.76,
                1709614800
            ],
            [
                28.94,
                1709701200
            ],
            [
                29.45,
                1709787600
            ],
            [
                29.25,
                1709874000
            ],
            [
                28.6,
                1710129600
            ],
            [
                28.47,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3904,
        "drug_name": "VUMERITY (Diroximel fumarate)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple sclerosis (MS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-10-30",
        "link": "http:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-alkermes-announce-fda-approval-vumeritytm-diroximel",
        "note": "FDA Approval announced October 30, 2019.",
        "company_entity_id": 375,
        "company_ticker": "BIIB",
        "company_name": "Biogen Inc.",
        "company_price": "227.3600",
        "company_change": -2.71,
        "company_percent_change": -1.1800000000000002,
        "company_optionable": 1,
        "company_number_of_shares": 145360798,
        "price_change_sparkline": [
            [
                246.66,
                1706677200
            ],
            [
                247.83,
                1706763600
            ],
            [
                243.72,
                1706850000
            ],
            [
                241.84,
                1707109200
            ],
            [
                245.55,
                1707195600
            ],
            [
                240.54,
                1707282000
            ],
            [
                240.3,
                1707368400
            ],
            [
                240.98,
                1707454800
            ],
            [
                244.74,
                1707714000
            ],
            [
                226.65,
                1707800400
            ],
            [
                220.74,
                1707886800
            ],
            [
                223.35,
                1707973200
            ],
            [
                219.08,
                1708059600
            ],
            [
                219.21,
                1708405200
            ],
            [
                221.11,
                1708491600
            ],
            [
                222.48,
                1708578000
            ],
            [
                223.32,
                1708664400
            ],
            [
                223.71,
                1708923600
            ],
            [
                223.94,
                1709010000
            ],
            [
                221.74,
                1709096400
            ],
            [
                216.99,
                1709182800
            ],
            [
                220.95,
                1709269200
            ],
            [
                221.02,
                1709528400
            ],
            [
                217.23,
                1709614800
            ],
            [
                217.56,
                1709701200
            ],
            [
                219.36,
                1709787600
            ],
            [
                223.24,
                1709874000
            ],
            [
                230.07,
                1710129600
            ],
            [
                227.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4660,
        "drug_name": "FLUZONE Quadrivalent (Influenza Vaccine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Influenza A - children 6-35 months of age.",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-04",
        "link": "http:\/\/www.news.sanofi.us\/2019-11-04-FDA-approves-Fluzone-R-High-Dose-Quadrivalent-Influenza-Vaccine-for-adults-65-years-of-age-and-older",
        "note": "sNDA FDA Approval announced for adults over 65 years of age.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5639,
        "drug_name": "Biosimilar pegfilgrastim",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pegfilgrastim biosimilar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-05",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/762942ff-a2f7-42f6-8dce-089ff38cac49",
        "note": "FDA Approval announced November 5, 2019.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5848,
        "drug_name": "REBLOZYL (Luspatercept)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Beta-thalassemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-08",
        "link": "http:\/\/investor.acceleronpharma.com\/news-releases\/news-release-details\/fda-approves-reblozylr-luspatercept-aamt-treatment-anemia-adults",
        "note": "FDA Approval announced November 8, 2019.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5848,
        "drug_name": "REBLOZYL (Luspatercept)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Beta-thalassemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-08",
        "link": "http:\/\/investor.acceleronpharma.com\/news-releases\/news-release-details\/fda-approves-reblozylr-luspatercept-aamt-treatment-anemia-adults",
        "note": "FDA Approval announced November 8, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2662,
        "drug_name": "BRUKINSA (zanubrutinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed or refractory mantle cell lymphoma (MCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-14",
        "link": "http:\/\/ir.beigene.com\/news-releases\/news-release-details\/us-fda-grants-beigenes-brukinsatm-zanubrutinib-accelerated",
        "note": "FDA Approval announced November 14, 2019.",
        "company_entity_id": 340,
        "company_ticker": "BGNE",
        "company_name": "BeiGene Ltd.",
        "company_price": "163.7500",
        "company_change": -0.78,
        "company_percent_change": -0.47,
        "company_optionable": 1,
        "company_number_of_shares": 104577940,
        "price_change_sparkline": [
            [
                148.23,
                1706677200
            ],
            [
                149.93,
                1706763600
            ],
            [
                144.48,
                1706850000
            ],
            [
                141.81,
                1707109200
            ],
            [
                153.58,
                1707195600
            ],
            [
                147.76,
                1707282000
            ],
            [
                142.88,
                1707368400
            ],
            [
                146.98,
                1707454800
            ],
            [
                146.57,
                1707714000
            ],
            [
                141.8,
                1707800400
            ],
            [
                145.87,
                1707886800
            ],
            [
                146.07,
                1707973200
            ],
            [
                148.23,
                1708059600
            ],
            [
                148.05,
                1708405200
            ],
            [
                150.8,
                1708491600
            ],
            [
                153.78,
                1708578000
            ],
            [
                155.1,
                1708664400
            ],
            [
                160.26,
                1708923600
            ],
            [
                179.69,
                1709010000
            ],
            [
                178.48,
                1709096400
            ],
            [
                165.65,
                1709182800
            ],
            [
                165.02,
                1709269200
            ],
            [
                167.86,
                1709528400
            ],
            [
                160.42,
                1709614800
            ],
            [
                159.52,
                1709701200
            ],
            [
                162.25,
                1709787600
            ],
            [
                158.52,
                1709874000
            ],
            [
                164.53,
                1710129600
            ],
            [
                163.75,
                1710216000
            ]
        ],
        "statuses": []
    }
]